Clinical Trial Update: Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del [Phase 3]

View source ↗

Summary

Clinical trial update reporting safety and pharmacokinetics of Lumacaftor/Ivacaftor in young children (2-5 years) with cystic fibrosis homozygous for F508del; s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Lumacaftor/Ivacaftor

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2018-10-30